NUCLEOSIDE PHOSPHORAMIDATES

• US 20110015146A1
• Filed: 12/23/2009
• Published: 01/20/2011
• Est. Priority Date: 12/23/2008
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Pharmasset Incorporated (Gilead Sciences Inc.)
• Inventors: Nagarathnam, Dhanapalan, SOFIA, MICHAEL JOSEPH, Wang, Peiyuan, Du, Jinfa
• Granted Patent: US 8,716,262 B2
• Time in Patent Office: Days
• US Class Current: 514/48
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A nucleoside compound having activity against hepatitis C virus is disclosed.

Claims

1. A compound represented by formula I, or its stereoisomers, salts, pharmaceutically acceptable salts, hydrates, solvates, crystalline, or metabolite forms thereof:

2. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and the compound as claimed in claim 1.

3. A use of the compound as claimed in claim 1 in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

4. A method of treatment in a subject in need thereof, which comprises administering a therapeutically effective amount of the compound as claimed in claim 1.

5. A method of treatment in a subject in need thereof, which comprises contacting at least one compound as claimed in claim 1 with at least one hepatitis C virus infected cell.

6. A compound represented by formula I, or a metabolite or salt or metabolite salt thereof:

7. A composition for the treatment and/or prophylaxis of any of the viral agents disclosed herein said composition comprising a pharmaceutically acceptable medium selected from among an excipient, carrier, diluent, and equivalent medium and the compound as claimed in claim 6.

8. A use of the compound as claimed in claim 6 in the manufacture of a medicament for the treatment of any condition the result of an infection by hepatitis C virus, West Nile virus, yellow fever virus, dengue virus, rhinovirus, polio virus, hepatitis A virus, bovine viral diarrhea virus or Japanese encephalitis virus.

9. A method of treatment in a subject in need thereof, which comprises administering a therapeutically effective amount of the compound as claimed in claim 6.

10. A method of treatment in a subject in need thereof, which comprises contacting at least one compound as claimed in claim 6 with at least one hepatitis C virus infected cell.